What is the significance of the tislelizumab sBLA acceptance in China?

The acceptance of the supplemental Biologics License Application (sBLA) for tislelizumab by China's NMPA signifies that the drug is now under regulatory review for potential approval in treating advanced or metastatic esophageal squamous cell carcinoma (ESCC). This moves the drug closer to market access for patients in China who have limited treatment options after failing first-line chemotherapy.

What does the conditional approval of KYPROLIS® mean for BeOne Medicines and patients?

A conditional approval allows KYPROLIS® (carfilzomib) to be available to patients with relapsed or refractory multiple myeloma (R/R MM) in China sooner, while the company may be required to conduct further studies to confirm its clinical benefit. For BeOne Medicines, this represents a new revenue stream and the first market entry for KYPROLIS in China under their agreement with Amgen.

What is the therapeutic indication for the approved KYPROLIS® combination therapy?

The KYPROLIS® (carfilzomib) in combination with dexamethasone is approved for adult patients in China with relapsed or refractory multiple myeloma (R/R MM) who have already been treated with at least two prior therapies, including both a proteasome inhibitor and an immunomodulatory agent.

How does the Amgen collaboration impact the KYPROLIS® approval?

The strategic collaboration between BeOne Medicines and Amgen is crucial as Amgen is the originator of KYPROLIS®. BeOne Medicines holds the license to market and sell KYPROLIS® in China under this agreement, enabling the drug's regulatory submission and subsequent conditional approval by the NMPA.

ONC/BEIGF 8-K SEC Disclosure

Summary

BeOne Medicines Ltd. (ONC) announced two significant regulatory milestones in China, as detailed in their July 9, 2021, 8-K filing. Firstly, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for tislelizumab, an anti-PD1 antibody, for the treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) in patients who have progressed on or are intolerant to first-line chemotherapy. This acceptance represents a crucial step towards potential market approval for tislelizumab in this indication within China. Secondly, and of immediate impact, the NMPA has granted conditional approval for KYPROLIS® (carfilzomib) for injection, in combination with dexamethasone. This approval is for adult patients suffering from relapsed or refractory multiple myeloma (R/R MM) who have undergone at least two prior treatment regimens including a proteasome inhibitor and an immunomodulatory agent. This marks the first approval of KYPROLIS in China, which BeiGene is able to market under a strategic collaboration with Amgen.

Key Highlights

1NMPA accepted supplemental Biologics License Application (sBLA) for tislelizumab in China for advanced/metastatic Esophageal Squamous Cell Carcinoma (ESCC).
2Tislelizumab is an anti-PD1 antibody targeting a significant unmet need in first-line chemotherapy-resistant ESCC patients.
3NMPA has conditionally approved KYPROLIS® (carfilzomib) for injection in China for relapsed or refractory Multiple Myeloma (R/R MM).
4KYPROLIS approval is for adult patients with R/R MM who have received at least two prior therapies (proteasome inhibitor and immunomodulatory agent).
5This is the first approval for KYPROLIS in China.
6BeiGene holds the license for KYPROLIS in China through a strategic collaboration with Amgen.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Jul 9, 2021)

Summary

Key Highlights

Frequently Asked Questions